Strides Pharma Science Limited — Investor Meet, 05-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Strides Pharma reported a strong Q2 FY26 with revenue up 4.6% YoY, gross margins at 57.8%, EBITDA growing 25.4% (19% margin), and operational PAT soaring 84% to INR140 Cr. H1 results also showed significant profitability improvements. The company prioritized profitability and consistent execution over pure top-line growth, especially in the US market, which grew 2% to $73 million. Other regulated markets and growth markets recorded robust 14% YoY growth, with an aspiration to mirror the US market in 2-3 years. Management remains focused on sustainable long-term value creation, disciplined capital allocation, and debt reduction, with net debt at INR1,449 Cr.